Osaic Holdings’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Osaic Holdings’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,825	Closed	-$1K	–	7716
2022 Q3	$1K	Hold	3,825	–	–	﹤0.01%	7183
2022 Q2	$3K	Hold	3,825	–	–	﹤0.01%	6814
2022 Q1	$74K	Hold	3,825	–	–	﹤0.01%	4807
2021 Q4	$10K	Hold	3,825	–	–	﹤0.01%	6301
2021 Q3	$12K	Buy	3,825 +1,000	+35%	+$3.34K	﹤0.01%	6118
2021 Q2	$10K	Hold	2,825	–	–	﹤0.01%	6112
2021 Q1	$10K	Hold	2,825	–	–	﹤0.01%	5897
2020 Q4	$10K	Hold	2,825	–	–	﹤0.01%	5536
2020 Q3	$11K	Hold	2,825	–	–	﹤0.01%	5242
2020 Q2	$13K	Buy	2,825 +825	+41%	+$3.65K	﹤0.01%	5064
2020 Q1	$7K	Buy	+2,000	New	+$9.15K	﹤0.01%	5222

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Osaic Holdings's PHAS Position: Q4 2022 in Review

Osaic Holdings sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 3,825 shares — an estimated $1K sold.

Osaic Holdings first reported a position in PHAS in Q1 2020 and held it in 11 quarters. The position peaked at $74K in Q1 2022. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

Osaic Holdings reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Osaic Holdings sold 3,825 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $1K.
Osaic Holdings first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
Osaic Holdings's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $74K in Q1 2022.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Osaic Holdings's 13F filing for Q4 2022, filed 10 Feb 2023.